Cargando…

MetAmyl: A METa-Predictor for AMYLoid Proteins

The aggregation of proteins or peptides in amyloid fibrils is associated with a number of clinical disorders, including Alzheimer's, Huntington's and prion diseases, medullary thyroid cancer, renal and cardiac amyloidosis. Despite extensive studies, the molecular mechanisms underlying the...

Descripción completa

Detalles Bibliográficos
Autores principales: Emily, Mathieu, Talvas, Anthony, Delamarche, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834037/
https://www.ncbi.nlm.nih.gov/pubmed/24260292
http://dx.doi.org/10.1371/journal.pone.0079722
_version_ 1782291928492015616
author Emily, Mathieu
Talvas, Anthony
Delamarche, Christian
author_facet Emily, Mathieu
Talvas, Anthony
Delamarche, Christian
author_sort Emily, Mathieu
collection PubMed
description The aggregation of proteins or peptides in amyloid fibrils is associated with a number of clinical disorders, including Alzheimer's, Huntington's and prion diseases, medullary thyroid cancer, renal and cardiac amyloidosis. Despite extensive studies, the molecular mechanisms underlying the initiation of fibril formation remain largely unknown. Several lines of evidence revealed that short amino-acid segments (hot spots), located in amyloid precursor proteins act as seeds for fibril elongation. Therefore, hot spots are potential targets for diagnostic/therapeutic applications, and a current challenge in bioinformatics is the development of methods to accurately predict hot spots from protein sequences. In this paper, we combined existing methods into a meta-predictor for hot spots prediction, called MetAmyl for METapredictor for AMYLoid proteins. MetAmyl is based on a logistic regression model that aims at weighting predictions from a set of popular algorithms, statistically selected as being the most informative and complementary predictors. We evaluated the performances of MetAmyl through a large scale comparative study based on three independent datasets and thus demonstrated its ability to differentiate between amyloidogenic and non-amyloidogenic polypeptides. Compared to 9 other methods, MetAmyl provides significant improvement in prediction on studied datasets. We further show that MetAmyl is efficient to highlight the effect of point mutations involved in human amyloidosis, so we suggest this program should be a useful complementary tool for the diagnosis of these diseases.
format Online
Article
Text
id pubmed-3834037
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38340372013-11-20 MetAmyl: A METa-Predictor for AMYLoid Proteins Emily, Mathieu Talvas, Anthony Delamarche, Christian PLoS One Research Article The aggregation of proteins or peptides in amyloid fibrils is associated with a number of clinical disorders, including Alzheimer's, Huntington's and prion diseases, medullary thyroid cancer, renal and cardiac amyloidosis. Despite extensive studies, the molecular mechanisms underlying the initiation of fibril formation remain largely unknown. Several lines of evidence revealed that short amino-acid segments (hot spots), located in amyloid precursor proteins act as seeds for fibril elongation. Therefore, hot spots are potential targets for diagnostic/therapeutic applications, and a current challenge in bioinformatics is the development of methods to accurately predict hot spots from protein sequences. In this paper, we combined existing methods into a meta-predictor for hot spots prediction, called MetAmyl for METapredictor for AMYLoid proteins. MetAmyl is based on a logistic regression model that aims at weighting predictions from a set of popular algorithms, statistically selected as being the most informative and complementary predictors. We evaluated the performances of MetAmyl through a large scale comparative study based on three independent datasets and thus demonstrated its ability to differentiate between amyloidogenic and non-amyloidogenic polypeptides. Compared to 9 other methods, MetAmyl provides significant improvement in prediction on studied datasets. We further show that MetAmyl is efficient to highlight the effect of point mutations involved in human amyloidosis, so we suggest this program should be a useful complementary tool for the diagnosis of these diseases. Public Library of Science 2013-11-19 /pmc/articles/PMC3834037/ /pubmed/24260292 http://dx.doi.org/10.1371/journal.pone.0079722 Text en © 2013 Emily et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Emily, Mathieu
Talvas, Anthony
Delamarche, Christian
MetAmyl: A METa-Predictor for AMYLoid Proteins
title MetAmyl: A METa-Predictor for AMYLoid Proteins
title_full MetAmyl: A METa-Predictor for AMYLoid Proteins
title_fullStr MetAmyl: A METa-Predictor for AMYLoid Proteins
title_full_unstemmed MetAmyl: A METa-Predictor for AMYLoid Proteins
title_short MetAmyl: A METa-Predictor for AMYLoid Proteins
title_sort metamyl: a meta-predictor for amyloid proteins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834037/
https://www.ncbi.nlm.nih.gov/pubmed/24260292
http://dx.doi.org/10.1371/journal.pone.0079722
work_keys_str_mv AT emilymathieu metamylametapredictorforamyloidproteins
AT talvasanthony metamylametapredictorforamyloidproteins
AT delamarchechristian metamylametapredictorforamyloidproteins